Clinical trial
Investigation of First Trimester Serum Vasohibin-1, Vasohibin-2, Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes
NCT06416995 is registered in ClinicalTrials.gov with Umraniye Education and Research Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigation of First Trimester Serum Vasohibin-1, Vasohibin-2, Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes
- Lead sponsor
- Umraniye Education and Research Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- March 3, 2023
- Completion date
- December 30, 2024
- Enrollment
- 88 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
fetal growth retardation, gestational diabetes, gestational hypertension, preeclampsia, preterm birth